Evidence map›Paper›PMID 38946827›Full record

ReviewWorld journal of clinical oncology2024

Overview of dyslipidemia and metabolic syndrome in myeloproliferative neoplasms.

Mihnea-Alexandru Găman, Bahadar Singh Srichawla, Yong-Feng Chen, Poulami Roy, Arkadeep Dhali, Ahmed Nahian, Muhammad Romail Manan, Vincent Kipkorir, Richard Christian Suteja, Lakshmi Venkata Simhachalam Kutikuppala and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mihnea-Alexandru GămanFaculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, Bucharest 050474, Romania.
Bahadar Singh SrichawlaDepartment of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01655, United States.
Yong-Feng ChenDepartment of Basic Medical Sciences, School of Medicine of Taizhou University, Taizhou University, Taizhou 318000, Zhejiang Province, China.
Poulami RoyDepartment of Medicine, North Bengal Medical College and Hospital, West Bengal 734012, India.
Arkadeep DhaliAcademic Department of Gastroenterology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield S5 7AU, United Kingdom.
Ahmed NahianLecom at Seton Hill, Greensburg, PA 15601, United States.
Muhammad Romail MananFaculty of Medicine, Services Hospital, Lahore 54000, Pakistan.
Vincent KipkorirDepartment of Human Anatomy and Physiology, University of Nairobi, Nairobi 00100, Kenya.
Richard Christian SutejaFaculty of Medicine, Udayana University, Denpasar, Bali 80361, Indonesia.
Lakshmi Venkata Simhachalam KutikuppalaDepartment of General Surgery, Dr. NTR University of Health Sciences, Vijayawada 520008, Andhra Pradesh, India.
Amelia Maria GămanDepartment of Pathophysiology, University of Medicine and Pharmacy of Craiova, Craiova 200349, Romania.
Camelia Cristina DiaconuDepartment of Internal Medicine, Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, Bucharest 050474, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myeloproliferative neoplasms (MPNs) occur due to the abnormal proliferation of one or more terminal myeloid cell lines in peripheral blood. Subjects suffering from MPNs display a high burden of cardiovascular risk factors, and thrombotic events are often the cause of death in this population of patients. Herein, we provide a brief overview of dyslipidemia and metabolic syndrome and their epidemiology in MPNs and examine the common molecular mechanisms between dyslipidemia, metabolic syndrome, and MPNs, with a special focus on cardiovascular risk, atherosclerosis, and thrombotic events. Furthermore, we investigate the impact of dyslipidemia and metabolic syndrome on the occurrence and survival of thrombosis in MPN patients, as well as the management of dyslipidemia in MPNs, and the impact of MPN treatment on serum lipid concentrations, particularly as side/adverse effects reported in the context of clinical trials.

Indexed as

Cardiovascular diseaseDiabetesEssential thrombocythemiaHypercholesterolemiaHypertriglyceridemiaInflammationMyelofibrosisObesityOxidative stressPolycythemia vera

Identifiers

PMID38946827
PMCPMC11212607

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.